CHIARLE, Roberto
CHIARLE, Roberto
BIOTECNOLOGIE MOLECOLARI E SCIENZE PER LA SALUTE
A Braf kinase-inactive mutant induces lung adenocarcinoma
2017-01-01 Nieto P.; Ambrogio C.; Esteban-Burgos L.; Gomez-Lopez G.; Blasco M.T.; Yao Z.; Marais R.; Rosen N.; Chiarle R.; Pisano D.G.; Barbacid M.; Santamaria D.
A LIBRETTO to orchestrate targeted therapy
2020-01-01 Marmarelis, Melina E; Chiarle, Roberto; Ambrogio, Chiara; Aggarwal, Charu
A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK+ lymphomas
2023-01-01 Rindone G.; Aroldi A.; Bossi E.; Verga L.; Zambrotta G.; Tarantino S.; Piazza R.; Mussolin L.; Chiarle R.; Gambacorti-Passerini C.
A theranostic approach based on the use of a dual boron/Gd agent to improve the efficacy of Boron Neutron Capture Therapy in the lung cancer treatment
2015-01-01 Alberti, Diego; Protti, Nicoletta; Toppino, Antonio; Deagostino, Annamaria; Lanzardo, Stefania; Bortolussi, Silva; Altieri, Saverio; Voena, Claudia; Chiarle, Roberto; Geninatti Crich, Simonetta; Aime, Silvio
Ablation of oncogenic ALK is a viable therapeutic approach fAblation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas
2006-01-01 PIVA R; CHIARLE R; MANAZZA AD; TAULLI R; SIMMONS W; AMBROGIO C; D'ESCAMARD V; PELLEGRINO E; PONZETTO C; PALESTRO G; INGHIRAMI G
Advances in cancer immunology and cancer immunotherapy
2016-01-01 Voena, Claudia*; Chiarle, Roberto
ALK in cancer: from function to therapeutic targeting
2025-01-01 Voena C.; Ambrogio C.; Iannelli F.; Chiarle R.
ALK inhibitors and vaccination against anaplastic lymphoma kinase (ALK) induce potent anti-tumor activity improving survival in non small cell lung carcinoma (NSCLC)
2012-01-01 C. Voena; M. Menotti; C. Mastini; F. Di Giacomo; D.L. Longo; C. Martinengo; S. Aime; F. Cavallo; G. Inghirami; R. Chiarle
ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells
2023-01-01 Bergaggio, Elisa; Tai, Wei-Tien; Aroldi, Andrea; Mecca, Carmen; Landoni, Elisa; Nüesch, Manuel; Mota, Ines; Metovic, Jasna; Molinaro, Luca; Ma, Leyuan; Alvarado, Diego; Ambrogio, Chiara; Voena, Claudia; Blasco, Rafael B; Li, Tongqing; Klein, Daryl; Irvine, Darrell J; Papotti, Mauro; Savoldo, Barbara; Dotti, Gianpietro; Chiarle, Roberto
ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer
2023-01-01 Mota, Ines; Patrucco, Enrico; Mastini, Cristina; Mahadevan, Navin R; Thai, Tran C; Bergaggio, Elisa; Cheong, Taek-Chin; Leonardi, Giulia; Karaca-Atabay, Elif; Campisi, Marco; Poggio, Teresa; Menotti, Matteo; Ambrogio, Chiara; Longo, Dario L; Klaeger, Susan; Keshishian, Hasmik; Sztupinszki, Zsófia M; Szallasi, Zoltan; Keskin, Derin B; Duke-Cohan, Jonathan S; Reinhold, Bruce; Carr, Steven A; Wu, Catherine J; Moynihan, Kelly D; Irvine, Darrell J; Barbie, David A; Reinherz, Ellis L; Voena, Claudia; Awad, Mark M; Blasco, Rafael B; Chiarle, Roberto
ALK protein tyrosine kinase, cells and methods embodying and using same
2005-01-01 R. Chiarle; G. Inghirami
ALK-dependent control of hypoxia-inducible factors mediates tumor growth and metastasis
2014-01-01 Martinengo, Cinzia; Poggio, Teresa; Menotti, Matteo; Scalzo, Maria Stella; Mastini, Cristina; Ambrogio, Chiara; Pellegrino, Elisa; Riera, Ludovica; Piva, Roberto; Ribatti, Domenico; Pastorino, Fabio; Perri, Patrizia; Ponzoni, Mirco; Wang, Qi; Voena, Claudia; Chiarle, Roberto
An In vivo Model of Met-Driven Lymphoma as a Tool to Explore the Therapeutic Potential of Met Inhibitors
2008-01-01 P. ACCORNERO; G. LATTANZIO; T. MANGANO; R. CHIARLE; R. TAULLI; F. BERSANI; P.E. FORNI; S. MIRETTI; C. SCUOPPO; W. DASTRU; J. CHRISTENSEN; T. CREPALDI; C. PONZETTO
An integrated humoral and cellular response is elicited in pancreatic cancer by alpha-enolase, a novel pancreatic ductal adenocarcinoma associated antigen
2009-01-01 P. Cappello; B Tomaino; R. Chiarle; P. Ceruti; A. Novarino; C. Castagnoli; P. Migliorini; G. Perconti; A. Giallongo; M. Milella; V. Monsurrò; S. Barbi; A. Scarpa; P. Nisticò; M. Giovarelli; F. Novelli
Anaplastic large cell lymphoma: one or more entities among T-cell lymphoma?
2009-01-01 Fornari A; Piva R; Chiarle R; Novero D; Inghirami G
Anaplastic large-cell lymphoma
2011-01-01 Inghirami G; Pileri SA; Chiarle R; Cuccuru G; Martinoglio B; Medico E; Pellegrino E; Piva R; Ruberto ML; Fornari A; Novero D; Chilosi M; Zamó A; Facchetti F; Lonardi S; De Chiara A; Fulciniti F; Doglioni C; Ponzoni M; Agnelli L; Neri A; Todoerti K; Agostinelli C; Piccaluga PP; Falini B; Tiacci E; Van Loo P; Tousseyn T; De Wolf-Peeters C; Geissinger E; Muller-Hermelink HK; Rosenwald A; Piris MA; Rodriguez ME.
Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death
2002-01-01 ZAMO A; R. CHIARLE; PIVA R; HOWES J; FAN Y; CHILOSI M; LEVY DE; INGHIRAMI G.
Anaplastic lymphoma kinase in human cancer
2011-01-01 Barreca A; Lasorsa E; Riera L; Machiorlatti R; Piva R; Ponzoni M; Kwee I; Bertoni F; Piccaluga PP; Pileri SA; Inghirami G; European T-Cell Lymphoma Study Group; Barreca A; Chiarle R; Cuccuru G; Inghirami G; Martinoglio B; Medico E; Pellegrino E; Piva R; Ruberto ML; Voena C; Fornari A; Novero D; Chilosi M; Zamò A; Facchetti F; Lonardi S; De Chiara A; Fulciniti F; Doglioni C; Ponzoni M; Agnelli L; Neri A; Todoerti K; Piccaluga PP; Pileri S; Falini B; Tiacci E; Van Loo P; Tousseyn T; De Wolf-Peeters C; Geissinger E; Konrad Muller-Hermelink H; Rosenwald A; Piris MA; Rodriguez ME
Anaplastic Lymphoma Kinase is an effective oncoantigen for lymphoma vaccination
2007-01-01 R. Chiarle; G. Inghirami; G. Forni
Anaplastic lymphoma kinase: an oncogene for tumor vaccination
2009-01-01 Mastini C; Martinengo C; Inghirami G; Chiarle R.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| A Braf kinase-inactive mutant induces lung adenocarcinoma | 2017 | Nieto P.; Ambrogio C.; Esteban-Burgos L.; Gomez-Lopez G.; Blasco M.T.; Yao Z.; Marais R.; Rosen N.; Chiarle R.; Pisano D.G.; Barbacid M.; Santamaria D. | |
| A LIBRETTO to orchestrate targeted therapy | 2020 | Marmarelis, Melina E; Chiarle, Roberto; Ambrogio, Chiara; Aggarwal, Charu | |
| A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK+ lymphomas | 2023 | Rindone G.; Aroldi A.; Bossi E.; Verga L.; Zambrotta G.; Tarantino S.; Piazza R.; Mussolin L.; Chiarle R.; Gambacorti-Passerini C. | |
| A theranostic approach based on the use of a dual boron/Gd agent to improve the efficacy of Boron Neutron Capture Therapy in the lung cancer treatment | 2015 | Alberti, Diego; Protti, Nicoletta; Toppino, Antonio; Deagostino, Annamaria; Lanzardo, Stefania; Bortolussi, Silva; Altieri, Saverio; Voena, Claudia; Chiarle, Roberto; Geninatti Crich, Simonetta; Aime, Silvio | |
| Ablation of oncogenic ALK is a viable therapeutic approach fAblation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas | 2006 | PIVA R; CHIARLE R; MANAZZA AD; TAULLI R; SIMMONS W; AMBROGIO C; D'ESCAMARD V; PELLEGRINO E; PONZETTO C; PALESTRO G; INGHIRAMI G | |
| Advances in cancer immunology and cancer immunotherapy | 2016 | Voena, Claudia*; Chiarle, Roberto | |
| ALK in cancer: from function to therapeutic targeting | 2025 | Voena C.; Ambrogio C.; Iannelli F.; Chiarle R. | |
| ALK inhibitors and vaccination against anaplastic lymphoma kinase (ALK) induce potent anti-tumor activity improving survival in non small cell lung carcinoma (NSCLC) | 2012 | C. Voena; M. Menotti; C. Mastini; F. Di Giacomo; D.L. Longo; C. Martinengo; S. Aime; F. Cavallo; G. Inghirami; R. Chiarle | |
| ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells | 2023 | Bergaggio, Elisa; Tai, Wei-Tien; Aroldi, Andrea; Mecca, Carmen; Landoni, Elisa; Nüesch, Manuel; Mota, Ines; Metovic, Jasna; Molinaro, Luca; Ma, Leyuan; Alvarado, Diego; Ambrogio, Chiara; Voena, Claudia; Blasco, Rafael B; Li, Tongqing; Klein, Daryl; Irvine, Darrell J; Papotti, Mauro; Savoldo, Barbara; Dotti, Gianpietro; Chiarle, Roberto | |
| ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer | 2023 | Mota, Ines; Patrucco, Enrico; Mastini, Cristina; Mahadevan, Navin R; Thai, Tran C; Bergaggio, Elisa; Cheong, Taek-Chin; Leonardi, Giulia; Karaca-Atabay, Elif; Campisi, Marco; Poggio, Teresa; Menotti, Matteo; Ambrogio, Chiara; Longo, Dario L; Klaeger, Susan; Keshishian, Hasmik; Sztupinszki, Zsófia M; Szallasi, Zoltan; Keskin, Derin B; Duke-Cohan, Jonathan S; Reinhold, Bruce; Carr, Steven A; Wu, Catherine J; Moynihan, Kelly D; Irvine, Darrell J; Barbie, David A; Reinherz, Ellis L; Voena, Claudia; Awad, Mark M; Blasco, Rafael B; Chiarle, Roberto | |
| ALK protein tyrosine kinase, cells and methods embodying and using same | 2005 | R. Chiarle; G. Inghirami | |
| ALK-dependent control of hypoxia-inducible factors mediates tumor growth and metastasis | 2014 | Martinengo, Cinzia; Poggio, Teresa; Menotti, Matteo; Scalzo, Maria Stella; Mastini, Cristina; Ambrogio, Chiara; Pellegrino, Elisa; Riera, Ludovica; Piva, Roberto; Ribatti, Domenico; Pastorino, Fabio; Perri, Patrizia; Ponzoni, Mirco; Wang, Qi; Voena, Claudia; Chiarle, Roberto | |
| An In vivo Model of Met-Driven Lymphoma as a Tool to Explore the Therapeutic Potential of Met Inhibitors | 2008 | P. ACCORNERO; G. LATTANZIO; T. MANGANO; R. CHIARLE; R. TAULLI; F. BERSANI; P.E. FORNI; S. MIRETTI; C. SCUOPPO; W. DASTRU; J. CHRISTENSEN; T. CREPALDI; C. PONZETTO | |
| An integrated humoral and cellular response is elicited in pancreatic cancer by alpha-enolase, a novel pancreatic ductal adenocarcinoma associated antigen | 2009 | P. Cappello; B Tomaino; R. Chiarle; P. Ceruti; A. Novarino; C. Castagnoli; P. Migliorini; G. Perconti; A. Giallongo; M. Milella; V. Monsurrò; S. Barbi; A. Scarpa; P. Nisticò; M. Giovarelli; F. Novelli | |
| Anaplastic large cell lymphoma: one or more entities among T-cell lymphoma? | 2009 | Fornari A; Piva R; Chiarle R; Novero D; Inghirami G | |
| Anaplastic large-cell lymphoma | 2011 | Inghirami G; Pileri SA; Chiarle R; Cuccuru G; Martinoglio B; Medico E; Pellegrino E; Piva R; Ruberto ML; Fornari A; Novero D; Chilosi M; Zamó A; Facchetti F; Lonardi S; De Chiara A; Fulciniti F; Doglioni C; Ponzoni M; Agnelli L; Neri A; Todoerti K; Agostinelli C; Piccaluga PP; Falini B; Tiacci E; Van Loo P; Tousseyn T; De Wolf-Peeters C; Geissinger E; Muller-Hermelink HK; Rosenwald A; Piris MA; Rodriguez ME. | |
| Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death | 2002 | ZAMO A; R. CHIARLE; PIVA R; HOWES J; FAN Y; CHILOSI M; LEVY DE; INGHIRAMI G. | |
| Anaplastic lymphoma kinase in human cancer | 2011 | Barreca A; Lasorsa E; Riera L; Machiorlatti R; Piva R; Ponzoni M; Kwee I; Bertoni F; Piccaluga PP; Pileri SA; Inghirami G; European T-Cell Lymphoma Study Group; Barreca A; Chiarle R; Cuccuru G; Inghirami G; Martinoglio B; Medico E; Pellegrino E; Piva R; Ruberto ML; Voena C; Fornari A; Novero D; Chilosi M; Zamò A; Facchetti F; Lonardi S; De Chiara A; Fulciniti F; Doglioni C; Ponzoni M; Agnelli L; Neri A; Todoerti K; Piccaluga PP; Pileri S; Falini B; Tiacci E; Van Loo P; Tousseyn T; De Wolf-Peeters C; Geissinger E; Konrad Muller-Hermelink H; Rosenwald A; Piris MA; Rodriguez ME | |
| Anaplastic Lymphoma Kinase is an effective oncoantigen for lymphoma vaccination | 2007 | R. Chiarle; G. Inghirami; G. Forni | |
| Anaplastic lymphoma kinase: an oncogene for tumor vaccination | 2009 | Mastini C; Martinengo C; Inghirami G; Chiarle R. |